Navigation Links
Elbit Imaging Ltd. Announces Interest Rate for the Next Interest Period for Series B Notes
Date:8/23/2011

TEL AVIV, Israel, August 23, 2011 /PRNewswire/ --

Elbit Imaging Ltd. ("EI" or the "Company") (NASDAQ: EMITF), announced today, in accordance with Section 4 of the "Terms Behind the Page" of Series B Notes of the Company, that the interest rate borne by Series B Notes for the interest period beginning on August 21, 2011 and ending on February 21, 2012 is 1.56055%.

About Elbit Imaging Ltd.

Elbit Imaging Ltd. operates in the following principal fields of business: (i) Commercial and Entertainment Centers - Initiation, construction and sale of shopping and entertainment centers and other mixed-use real property projects, predominantly in the retail sector, located in Central and Eastern Europe and in India; (ii) U.S. Real Property - Investment in commercial real property in the United States; (iii) Hotels - Hotel operation and management, primarily in major European cities; (iv) Medical Industries - (a) research and development, production and marketing of magnetic resonance imaging guided focused ultrasound treatment equipment and (b) development of stem cell population expansion technologies and stem cell therapy products for transplantation and regenerative medicine; (v) Residential Projects - Initiation, construction and sale of residential projects and other mixed-use real property projects, predominately residential, located primarily in India and in Eastern Europe; (vi) Fashion Apparel - Distribution and marketing of fashion apparel and accessories in Israel; and (vii) Other Activities - (a) venture capital investments and (b) investments in hospitals and farm and dairy plants in India. We have presently decided to suspend our investment activities in hospitals and farm and dairy plants in India until we are satisfied that the economy has recovered sufficiently to resume such activities.

Any forward-looking statements in our releases include statements regarding the intent, belief or current expectations of Elbit Imaging Ltd. and our management about our business, financial condition, results of operations, and its relationship with its employees and the condition of our properties. Words such as "believe," "expect," "intend," "estimate" and similar expressions are intended to identify forward-looking statements but are not the exclusive means of identifying such statements. Actual results may differ materially from those projected, expressed or implied in the forward-looking statements as a result of various factors including, without limitation, the factors set forth in our filings with the Securities and Exchange Commission including, without limitation, Item 3.D of our annual report on Form 20-F for the fiscal year ended December 31, 2010, under the caption "Risk Factors." Any forward-looking statements contained in our releases speak only as of the date of such release, and we caution existing and prospective investors not to place undue reliance on such statements. Such forward-looking statements do not purport to be predictions of future events or circumstances, and therefore, there can be no assurance that any forward-looking statement contained our releases will prove to be accurate. We undertake no obligation to update or revise any forward-looking statements.


For Further Information:


    
    Company Contact:
    Dudi Machluf
    Chief Executive Officer (Co-CEO)
    Tel: +972-3-608-6024
    dudim@elbitimaging.com 

    
    Investor Contact:
    Mor Dagan
    Investor Relations
    Tel: +972-3-516-7620
    mor@km-ir.co.il
 



'/>"/>
SOURCE Elbit Imaging Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Elbit Imaging Announces Share Purchase Agreement With Enter Holdings
2. Elbit Imaging Announces Insightec Treats First Prostate Cancer Patients in Clinical Trials
3. Elbit Imaging Ltd. Announces First Quarter Results for 2010
4. Elbit Imaging Announces Data Monitoring Committee Recommends Continuation of Phase III Study of StemEx(R), a Cord Blood Stem Cell Product, for Leukemia and Lymphoma
5. Elbit Imaging Announces InSightecs First Non-Invasive Technology for Treatment of Uterine Fibroids Awarded MHLW Approval in Japan
6. Elbit Imaging Ltd. Announces Sale of Plaza Centers Shares
7. Elbit Imaging Ltd. Announces - Swiss Team Uses InSightecs ExAblate(R) 4000 Brain System to Treat Patients With Functional Brain Disorders
8. Pathologists Gather to Focus on Advances in Molecular Testing, Digital Imaging, and Biospecimens
9. Strategic Assessments of Leading North American Diagnostic Imaging Market Players
10. MarketsandMarkets: "Radiopharmaceuticals for Therapy and PET/SPECT Imaging" Market to reach $4,734 Million by 2015
11. Unrestricted Access to Advanced Imaging a Top Priority for Consumers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)... DIEGO , Sept. 22, 2017 AVACEN ... medical device is now successfully helping those with the ... Fibromyalgia diagnosed Amanda in Essex, ... dressed and washing my hair, experiencing no sleep at ... in painful spasm… I cannot recommend [the AVACEN 100] ...
(Date:9/18/2017)... KALAMAZOO, Mich. , Sept. 18, 2017 /PRNewswire/ ... and OptiMed Specialty Pharmacy of Kalamazoo, Mich. ... a strategic hub service that expedites and streamlines patient ... spirometer, Spiro PD 2.0, and wellness management services.  ... a medical device used to measure lung function for ...
(Date:9/12/2017)... 12, 2017   EcoVadis , the leading platform for environmental, social ... annual edition of its Global CSR Risk and Performance Index. The report ... based on Scorecard Ratings that analyzed nearly 800,000 data points across the ... ... ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th ... Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s CEO, ... The fun run is geared towards children of all ages; it is a non-competitive, ...
(Date:10/13/2017)... VA (PRWEB) , ... October 13, 2017 , ... ... of DevOps and Agile Software Development, has been awarded a contract by the ... Blanket Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies ...
(Date:10/12/2017)... ... 12, 2017 , ... First Healthcare Compliance (FHC), an industry ... a range of technology and learning solutions at the 68th Annual American Healthcare ... be held October 14–18, 2017 at the Mandalay Bay Resort in Las Vegas, ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... products to meet the demand of today’s consumer and regulatory authorities worldwide. From ... probiotic experts and tested to meet the highest standard. , These products ...
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, a nationally recognized health ... expanded their existing home health joint venture through an agreement, effective October 1, ... joint venture home health company with Asante, delivering clinically integrated care, for the ...
Breaking Medicine News(10 mins):